NEW YORK (GenomeWeb News) – RNA-based diagnostics and drug developer ExonHit Therapeutics will provide transcriptomics analysis services and its SpliceArray to a European public and private-funded consortium that is focused on identifying new biomarkers for Alzheimer's disease, the Paris-based company said today.
The company said that it will provide its SpliceArray technology and related services to the European Innovative Medicines Initiative (IMI) consortium's PharmaCog effort, which is focused on developing new translational tools, and ultimately a new drug candidate for Alzheimer's treatment.
"ExonHit's unique understanding of transcriptomics analysis will be critical to PharmaCog as it could enable the identification of blood-based markers of disease presence and progression," Olivier Blin, who heads the Center of Clinical Pharmacology and Therapeutic Evaluations at Marseilles Hospital, in a statement. "Such markers are critical in drug development because they provide scientists with greater insights on how results found during preclinical testing are more likely to be reproduced in the clinic."
ExonHit offer the AclarusDx Alzheimer's test for stratifying patients, and it also has developed a Phase 2 drug compound for Alzheimer's disease.
IMI has a total budget of €2 billion ($2.7 billion), and PharmaCog has a budget of €20 million, with €9 million coming from IMI and €11 million from the European Federation of Pharmaceutical Industries and Associations.